MAMDC4

Across TCGA pan-cancer cohorts, MAMDC4 Mutation is linked to patient survival in 3 of 34 cancer types, making it a survival-associated MAMDC4 data layer compared with 20 for mass-spec protein.

The strongest signal is observed in thymoma (THYM), where higher MAMDC4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated MAMDC4 expression acts as an unfavorable survival marker.

THYM, HNSC, and UCEC are the cancer types where MAMDC4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
THYM	OS	Median	II,III,IV	0.604	0.967	.003	18	view →
HNSC	OS	Median	IV	0.021	0.643	<.001	6	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

MAMDC4–THYM (OS)

Open the THYM breakdown →